WHAT IS NARCOLEPSY?

- Narcolepsy is a sleep condition impacting the timing of rapid eye movement (REM) sleep.
- Symptoms can include excessive daytime sleepiness, sleep disruption, cataplexy, sleep paralysis and hypnagogic/hypnopompic hallucinations.

Narcolepsy is estimated to impact approximately 1 of every 2,000 people.

KP1077 RESEARCH

- KP1077 in IH is currently in a Phase 2 clinical trial, with enrolling at over 30 clinical trial sites across the US, evaluating safety and efficacy in IH patients. Topline results are anticipated in 2023.
- More information can be found at KP1077D01.com or clinicaltrials.gov (NCT05668754).
- In 2023, Zevra will commence necessary Phase 1 studies in tandem with the Phase 2 study, and eventually a Phase 3 study in IH. Zevra is exploring the potential for a Phase 3 study in narcolepsy. Based on previous research in other indications, KP1077 already has an established and robust safety profile.
- Additional Phase 1 studies will investigate parameters such as dosage timing and other attributes, including administration with food at the highest to-be-marketed dose.

RESOURCES

Zevra Therapeutics is a rare disease company melding science, data, and patient need to create transformational therapies for diseases with limited or no treatment options.

More information is available at Zevra.com